BG107988A - Стабилизирани препарати за локално третиране с бривудин - Google Patents

Стабилизирани препарати за локално третиране с бривудин Download PDF

Info

Publication number: BG107988A
Authority: BG; Bulgaria
Prior art keywords: iron oxide; brivudine; titanium dioxide; oxide; pharmaceutical composition
Prior art date: 2001-01-17

Application number

BG107988A

Other languages

Bulgarian (bg)

English (en)

Inventor

Ulrike Gehlert

Karsten Groger

Reinhard Schmitz

Karl-Heinz Schraeder

Andreas Schraeder

Marc Wihsmann

Carlo A. Maggi

Stefano Manzini

Bettina Stubinski

Original Assignee

Berlin-Chemie Ag

Menarini Ricerche S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-17

Filing date

2003-07-10

Publication date

2004-09-30

2003-07-10 Application filed by Berlin-Chemie Ag, Menarini Ricerche S.P.A. filed Critical Berlin-Chemie Ag

2004-09-30 Publication of BG107988A publication Critical patent/BG107988A/bg

Links

ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 title claims abstract description 56
229960001169 brivudine Drugs 0.000 title claims abstract description 54
239000012049 topical pharmaceutical composition Substances 0.000 title claims description 3
239000000049 pigment Substances 0.000 claims abstract description 16
230000000699 topical effect Effects 0.000 claims abstract description 11
229910044991 metal oxide Inorganic materials 0.000 claims abstract description 8
150000004706 metal oxides Chemical class 0.000 claims abstract description 8
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 67
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 48
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 45
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
239000004408 titanium dioxide Substances 0.000 claims description 33
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 28
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
-1 polyoxyethylene monostearate Polymers 0.000 claims description 23
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 22
239000006071 cream Substances 0.000 claims description 20
239000008194 pharmaceutical composition Substances 0.000 claims description 17
235000011187 glycerol Nutrition 0.000 claims description 14
239000000377 silicon dioxide Substances 0.000 claims description 14
239000003871 white petrolatum Substances 0.000 claims description 14
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 12
239000012188 paraffin wax Substances 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 11
239000011787 zinc oxide Substances 0.000 claims description 11
WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 claims description 10
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 10
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 10
229960000686 benzalkonium chloride Drugs 0.000 claims description 9
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 9
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 9
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 8
229940082500 cetostearyl alcohol Drugs 0.000 claims description 8
239000004205 dimethyl polysiloxane Substances 0.000 claims description 8
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 8
229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 8
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 8
229940045860 white wax Drugs 0.000 claims description 8
241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 7
239000005662 Paraffin oil Substances 0.000 claims description 7
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 6
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
239000000499 gel Substances 0.000 claims description 6
239000000017 hydrogel Substances 0.000 claims description 6
235000019271 petrolatum Nutrition 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
239000001593 sorbitan monooleate Substances 0.000 claims description 6
229940035049 sorbitan monooleate Drugs 0.000 claims description 6
235000011069 sorbitan monooleate Nutrition 0.000 claims description 6
NJESAXZANHETJV-UHFFFAOYSA-N 4-methylsalicylic acid Chemical compound CC1=CC=C(C(O)=O)C(O)=C1 NJESAXZANHETJV-UHFFFAOYSA-N 0.000 claims description 5
239000000839 emulsion Substances 0.000 claims description 5
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
239000004166 Lanolin Substances 0.000 claims description 4
229960000541 cetyl alcohol Drugs 0.000 claims description 4
AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims description 4
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
229940039717 lanolin Drugs 0.000 claims description 4
235000019388 lanolin Nutrition 0.000 claims description 4
235000019359 magnesium stearate Nutrition 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
229940083037 simethicone Drugs 0.000 claims description 4
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 4
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 3
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 3
229960002446 octanoic acid Drugs 0.000 claims description 3
239000000473 propyl gallate Substances 0.000 claims description 3
229940075579 propyl gallate Drugs 0.000 claims description 3
235000010388 propyl gallate Nutrition 0.000 claims description 3
239000004147 Sorbitan trioleate Substances 0.000 claims description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 2
235000014113 dietary fatty acids Nutrition 0.000 claims description 2
239000000194 fatty acid Substances 0.000 claims description 2
229930195729 fatty acid Natural products 0.000 claims description 2
150000004665 fatty acids Chemical class 0.000 claims description 2
235000019337 sorbitan trioleate Nutrition 0.000 claims description 2
229960000391 sorbitan trioleate Drugs 0.000 claims description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 1
235000021355 Stearic acid Nutrition 0.000 claims 1
208000005181 Varicella Zoster Virus Infection Diseases 0.000 claims 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 1
229910052742 iron Inorganic materials 0.000 claims 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
239000008117 stearic acid Substances 0.000 claims 1
208000010531 varicella zoster infection Diseases 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 8
238000001782 photodegradation Methods 0.000 abstract description 5
239000003381 stabilizer Substances 0.000 abstract description 3
235000010215 titanium dioxide Nutrition 0.000 description 21
229960004150 aciclovir Drugs 0.000 description 11
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 11
239000004615 ingredient Substances 0.000 description 8
239000008213 purified water Substances 0.000 description 8
YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 6
JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 6
239000003443 antiviral agent Substances 0.000 description 6
229960001179 penciclovir Drugs 0.000 description 6
241000701085 Human alphaherpesvirus 3 Species 0.000 description 5
239000000126 substance Substances 0.000 description 4
208000004898 Herpes Labialis Diseases 0.000 description 3
208000007514 Herpes zoster Diseases 0.000 description 3
208000029433 Herpesviridae infectious disease Diseases 0.000 description 3
206010067152 Oral herpes Diseases 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
239000002085 irritant Substances 0.000 description 3
231100000021 irritant Toxicity 0.000 description 3
230000000176 photostabilization Effects 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
241001529453 unidentified herpesvirus Species 0.000 description 3
JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
239000004904 UV filter Substances 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
229960004396 famciclovir Drugs 0.000 description 2
GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
238000000034 method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
238000003756 stirring Methods 0.000 description 2
VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
UWYHEGBHZPUZEE-UHFFFAOYSA-N 2,3-dihydroxy-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(O)=C1O UWYHEGBHZPUZEE-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010065764 Mucosal infection Diseases 0.000 description 1
229910000805 Pig iron Inorganic materials 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001278 adipic acid derivatives Chemical class 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229940105990 diglycerin Drugs 0.000 description 1
GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
229940080345 gamma-cyclodextrin Drugs 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000012994 industrial processing Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
235000019136 lipoic acid Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000009430 psychological distress Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960002663 thioctic acid Drugs 0.000 description 1
230000007442 viral DNA synthesis Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Virology (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Biotechnology (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG107988A 2001-01-17 2003-07-10 Стабилизирани препарати за локално третиране с бривудин BG107988A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01100968		2001-01-17
PCT/EP2002/000163 WO2002056913A2 (en)	2001-01-17	2002-01-10	Stabilized brivudine topical formulations containing metal oxide pigments

Publications (1)

Publication Number	Publication Date
BG107988A true BG107988A (bg)	2004-09-30

Family

ID=8176229

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107988A BG107988A (bg)	2001-01-17	2003-07-10	Стабилизирани препарати за локално третиране с бривудин

Country Status (28)

Country	Link
US (1)	US20040087602A1 (cs)
EP (1)	EP1365772A2 (cs)
JP (1)	JP2004519460A (cs)
KR (1)	KR20030070109A (cs)
CN (1)	CN1236777C (cs)
AR (1)	AR035530A1 (cs)
AU (1)	AU2002244642B2 (cs)
BG (1)	BG107988A (cs)
BR (1)	BR0206478A (cs)
CA (1)	CA2434743A1 (cs)
CZ (1)	CZ20031912A3 (cs)
EE (1)	EE200300322A (cs)
HR (1)	HRP20030559A2 (cs)
HU (1)	HUP0302741A3 (cs)
IL (1)	IL156933A0 (cs)
MA (1)	MA26266A1 (cs)
MX (1)	MXPA03006307A (cs)
MY (1)	MY136633A (cs)
NO (1)	NO20033206L (cs)
PE (1)	PE20020818A1 (cs)
PL (1)	PL365741A1 (cs)
RU (1)	RU2280453C2 (cs)
SK (1)	SK8992003A3 (cs)
TN (1)	TNSN03036A1 (cs)
UA (1)	UA80673C2 (cs)
WO (1)	WO2002056913A2 (cs)
YU (1)	YU57103A (cs)
ZA (1)	ZA200305437B (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102005046769A1 (de) *	2005-09-29	2007-04-05	Berlin-Chemie Ag	Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus)
FR2936706B1 (fr) *	2008-10-08	2010-12-17	Oreal	Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane
KR20110117133A (ko) *	2009-01-29	2011-10-26	다이닛본 스미토모 세이야꾸 가부시끼가이샤	내핵을 갖는 구강 내 붕괴 정
BR112017019920B1 (pt) *	2015-03-19	2023-11-07	Daiichi Sankyo Company, Limited	Preparação sólida farmacêutica, e, método para estabilização de uma preparação sólida farmacêutica
CN104988791A (zh) *	2015-06-25	2015-10-21	广东义晟实业有限公司	一种抗病毒添加剂及添加该添加剂的胶水和uv漆

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0072137A1 (en) *	1981-08-01	1983-02-16	Beecham Group Plc	Antiviral deoxyuridine compounds
HU196038B (en) *	1987-08-07	1988-09-28	Mta Koezponti Kemiai Kutato In	Process for producing antiherpetic pharmaceutics for external use, containing 5-isopropyl-2'-beta-deoxy-uridine
DE4122337A1 (de) *	1991-07-05	1993-01-14	Cedona Pharm Bv	Pharmazeutische zubereitung
FR2737118B1 (fr) *	1995-07-28	1997-09-05	Oreal	Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
GB9521454D0 (en) *	1995-10-19	1995-12-20	Kappa Pharmaceuticals Ltd	Compositions for the treatment of conditions caused by herpes virus
US6558710B1 (en) *	1999-06-14	2003-05-06	Helen Rebecca Godfrey	Topical zinc compositions and methods of use
DE10162593A1 (de) *	2001-12-19	2003-07-03	Menarini Ricerche Spa	Stabilisierte topische Brivudin-Formulierungen

2001
- 2001-12-24 MY MYPI20015863A patent/MY136633A/en unknown
2002
- 2002-01-10 BR BR0206478-2A patent/BR0206478A/pt not_active IP Right Cessation
- 2002-01-10 HU HU0302741A patent/HUP0302741A3/hu unknown
- 2002-01-10 RU RU2003121639/15A patent/RU2280453C2/ru not_active IP Right Cessation
- 2002-01-10 MX MXPA03006307A patent/MXPA03006307A/es not_active Application Discontinuation
- 2002-01-10 CN CNB028037448A patent/CN1236777C/zh not_active Expired - Fee Related
- 2002-01-10 EE EEP200300322A patent/EE200300322A/xx unknown
- 2002-01-10 SK SK899-2003A patent/SK8992003A3/sk not_active Application Discontinuation
- 2002-01-10 IL IL15693302A patent/IL156933A0/xx unknown
- 2002-01-10 HR HR20030559A patent/HRP20030559A2/hr not_active Application Discontinuation
- 2002-01-10 US US10/466,305 patent/US20040087602A1/en not_active Abandoned
- 2002-01-10 CA CA002434743A patent/CA2434743A1/en not_active Abandoned
- 2002-01-10 YU YU57103A patent/YU57103A/sh unknown
- 2002-01-10 AU AU2002244642A patent/AU2002244642B2/en not_active Ceased
- 2002-01-10 EP EP02712810A patent/EP1365772A2/en not_active Withdrawn
- 2002-01-10 JP JP2002557420A patent/JP2004519460A/ja active Pending
- 2002-01-10 KR KR10-2003-7009444A patent/KR20030070109A/ko not_active Ceased
- 2002-01-10 WO PCT/EP2002/000163 patent/WO2002056913A2/en not_active Ceased
- 2002-01-10 CZ CZ20031912A patent/CZ20031912A3/cs unknown
- 2002-01-10 PL PL02365741A patent/PL365741A1/xx not_active Application Discontinuation
- 2002-01-16 AR ARP020100151A patent/AR035530A1/es not_active Application Discontinuation
- 2002-01-16 PE PE2002000027A patent/PE20020818A1/es not_active Application Discontinuation
- 2002-10-01 UA UA2003076388A patent/UA80673C2/uk unknown
2003
- 2003-06-30 MA MA27219A patent/MA26266A1/fr unknown
- 2003-07-08 TN TNPCT/EP2002/000163A patent/TNSN03036A1/fr unknown
- 2003-07-10 BG BG107988A patent/BG107988A/bg unknown
- 2003-07-15 ZA ZA200305437A patent/ZA200305437B/xx unknown
- 2003-07-15 NO NO20033206A patent/NO20033206L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2002244642B2 (en)	2005-12-15
KR20030070109A (ko)	2003-08-27
UA80673C2 (en)	2007-10-25
ZA200305437B (en)	2004-07-15
WO2002056913A3 (en)	2002-11-07
EE200300322A (et)	2003-10-15
HRP20030559A2 (en)	2005-06-30
MA26266A1 (fr)	2004-09-01
TNSN03036A1 (en)	2005-04-08
HUP0302741A2 (hu)	2003-11-28
RU2003121639A (ru)	2005-02-10
CA2434743A1 (en)	2002-07-25
BR0206478A (pt)	2003-12-30
RU2280453C2 (ru)	2006-07-27
WO2002056913A2 (en)	2002-07-25
PE20020818A1 (es)	2002-10-21
HUP0302741A3 (en)	2007-06-28
IL156933A0 (en)	2004-02-08
JP2004519460A (ja)	2004-07-02
AR035530A1 (es)	2004-06-02
PL365741A1 (en)	2005-01-10
MXPA03006307A (es)	2003-09-16
CN1486185A (zh)	2004-03-31
NO20033206D0 (no)	2003-07-15
EP1365772A2 (en)	2003-12-03
CZ20031912A3 (cs)	2004-01-14
CN1236777C (zh)	2006-01-18
NO20033206L (no)	2003-07-15
SK8992003A3 (en)	2003-11-04
YU57103A (sh)	2006-08-17
US20040087602A1 (en)	2004-05-06
MY136633A (en)	2008-11-28

Publication	Publication Date	Title
US4963555A (en)	1990-10-16	Formulations of heterocyclic compounds
CA1172169A (en)	1984-08-07	Formulations of heterocyclic compounds
JPH09506865A (ja)	1997-07-08	新規組成物
KR20010101715A (ko)	2001-11-14	외용 조성물
ITMI970408A1 (it)	1998-08-25	Sistemi gelificati di nimesulide per uso topico
RS57103B1 (sr)	2018-06-29	Supstituisani derivati piridina korisni kao inhibitori c-fms kinaze
DE69411090T2 (de)	1999-01-07	Kosmetisches Präparat mit einer Zusammensetzung einer Superoxyd Dismutase und eines Melaninpigmentes
WO1997034607A1 (en)	1997-09-25	Topical formulations of aciclovir
BG107988A (bg)	2004-09-30	Стабилизирани препарати за локално третиране с бривудин
JP4591746B2 (ja)	2010-12-01	難溶性抗ウイルス成分含有水溶性外用剤組成物
AU2002244642A1 (en)	2003-02-13	Stabilized brivudine topical formulations containing metal oxide pigments
RU2288720C2 (ru)	2006-12-10	Жидкая композиция, содержащая миноксидил
NZ205587A (en)	1986-08-08	Composition comprising undecylenic acid for treating herpes simplex i
HU196038B (en)	1988-09-28	Process for producing antiherpetic pharmaceutics for external use, containing 5-isopropyl-2'-beta-deoxy-uridine
AU768989B2 (en)	2004-01-15	Aciclovir compositions containing dimethicone
JP2000178118A (ja)	2000-06-27	保湿剤及び皮膚化粧料並びに入浴剤
JPH05124923A (ja)	1993-05-21	メラニン生成抑制外用剤
US20240358625A1 (en)	2024-10-31	Stabilization of mycosporine-like amino acids
WO1997045123A1 (en)	1997-12-04	Topical pharmaceutical formulations comprising aciclovir
KR20120103768A (ko)	2012-09-20	ｐＨ 조절을 통해 안정화된 프룩토오스 1,6-디포스페이트 화합물을 함유하는 피부 외용제 조성물
JPH05124947A (ja)	1993-05-21	メラニン生成抑制外用剤
JPH11501625A (ja)	1999-02-09	ヒト・ヘルペスウイルス−８の治療に対するペンシクロビルの使用
RU2333752C1 (ru)	2008-09-20	Противовирусное средство
JPH05124948A (ja)	1993-05-21	メラニン生成抑制外用剤
JPH11106323A (ja)	1999-04-20	皮膚外用剤